Sangamo Therapeutics, Inc

SGMOCIK 0001001233 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 30, 2026. Sentiment + YoY language diff vs prior year. Read sections →

Signal:Material rewriteFull-doc fallback

Full filing:tone -0.0002Δ+0.014526% similar+279/-1515 ¶

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

May 14, 2026no items parsed Apr 29, 2026no items parsed Mar 30, 2026no items parsed Feb 4, 2026no items parsed Feb 3, 2026no items parsed

YoY shift: Bullish

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K. This filing is 1.45pp more bullish than last year's.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Sangamo Therapeutics, Inc

Name	Roles	Filings
Beers Courtney	Director	3
Horn Margaret A	Director	3
Ramelmeier Rolf Andrew	Officer	3
Schott Robert J.	Officer	2
Biogen Inc.	10% Owner	1

Showing 16-20 of 23

Per pagePrevPage 4 of 5Next

All filings

175 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Nov 26, 2025	Willoughby Scott B. SVP, CHIEF LEGAL OFFICER, SECY	FTax	2,035	$0.4166	$848

Filed		Top transaction	Shares	Price	Value